CS261637B1 - Antihepatotoxic pharmaceutical preparat - Google Patents

Antihepatotoxic pharmaceutical preparat Download PDF

Info

Publication number: CS261637B1
Authority: CS; Czechoslovakia
Prior art keywords: pharmaceutical composition; phospholipids; silymarin; composition according; phosphatidylcholine
Prior art date: 1985-07-17

Application number

CS865456A

Other languages

Czech (cs)

English (en)

Other versions

CS545686A1 (en

Inventor

Ezio Bombardelli

Maria Jose Magistretti

Original Assignee

Ezio Bombardelli

Maria Jose Magistretti

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-17

Filing date

1986-07-17

Publication date

1989-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11184200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CS261637(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1986-07-17 Application filed by Ezio Bombardelli, Maria Jose Magistretti filed Critical Ezio Bombardelli

1988-07-15 Publication of CS545686A1 publication Critical patent/CS545686A1/cs

1989-02-10 Publication of CS261637B1 publication Critical patent/CS261637B1/cs

Links

230000001929 anti-hepatotoxic effect Effects 0.000 title claims description 5
SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims abstract description 23
SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims abstract description 23
239000000203 mixture Substances 0.000 claims abstract description 22
150000003904 phospholipids Chemical class 0.000 claims abstract description 22
229960004245 silymarin Drugs 0.000 claims abstract description 21
235000017700 silymarin Nutrition 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
125000002252 acyl group Chemical group 0.000 claims abstract description 4
210000004185 liver Anatomy 0.000 claims description 13
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
235000010469 Glycine max Nutrition 0.000 claims description 3
244000068988 Glycine max Species 0.000 claims description 3
CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
239000007910 chewable tablet Substances 0.000 claims description 3
229950004878 silicristin Drugs 0.000 claims description 3
229950004304 silidianin Drugs 0.000 claims description 3
BMLIIPOXVWESJG-LMBCONBSSA-N silychristin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC(=C3)[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-LMBCONBSSA-N 0.000 claims description 3
BMLIIPOXVWESJG-UHFFFAOYSA-N silychristin A Natural products C1=C(O)C(OC)=CC(C2C(C3=C(C(=CC(=C3)C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-UHFFFAOYSA-N 0.000 claims description 3
CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 claims description 3
FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 2
VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
229940043175 silybin Drugs 0.000 claims description 2
235000014899 silybin Nutrition 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
208000019423 liver disease Diseases 0.000 abstract description 6
208000030090 Acute Disease Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
241000700159 Rattus Species 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 3
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
229960001231 choline Drugs 0.000 description 3
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
239000012528 membrane Substances 0.000 description 3
235000015205 orange juice Nutrition 0.000 description 3
231100000572 poisoning Toxicity 0.000 description 3
230000000607 poisoning effect Effects 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
102000003929 Transaminases Human genes 0.000 description 2
108090000340 Transaminases Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
235000020661 alpha-linolenic acid Nutrition 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000035699 permeability Effects 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CS865456A 1985-07-17 1986-07-17 Antihepatotoxic pharmaceutical preparat CS261637B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT21603/85A IT1187687B (it)	1985-07-17	1985-07-17	Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi

Publications (2)

Publication Number	Publication Date
CS545686A1 CS545686A1 (en)	1988-07-15
CS261637B1 true CS261637B1 (en)	1989-02-10

Family

ID=11184200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS865456A CS261637B1 (en)	1985-07-17	1986-07-17	Antihepatotoxic pharmaceutical preparat

Country Status (6)

Country	Link
EP (1)	EP0209037B1 (fr)
JP (1)	JPS6222719A (fr)
AT (1)	ATE50499T1 (fr)
CS (1)	CS261637B1 (fr)
DE (1)	DE3669106D1 (fr)
IT (1)	IT1187687B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1190370B (it) *	1985-06-19	1988-02-16	Zambon Spa	Composizione farmaceutica solida per uso orale
IT1201149B (it) *	1987-01-14	1989-01-27	Indena Spa	Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
DE4401902C2 (de) *	1994-01-24	2000-02-03	Madaus Ag	Verwendung von Flavolignanen als Adjuvans in der Tumortherapie
DE19501266A1 (de) *	1995-01-18	1996-07-25	Madaus Ag	Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
CN1061239C (zh) *	1995-01-20	2001-01-31	李叔文	爱滋病特效治疗剂
RU2133122C1 (ru) *	1998-10-14	1999-07-20	Научно-исследовательский институт биомедицинской химии РАМН	Композиция, обладающая свойствами репарировать биологические мембраны
US6191121B1 (en) *	2000-04-06	2001-02-20	Nicholas V. Perricone	Treatment of skin damage using polyenylphosphatidylcholine
US6979459B1 (en)	2000-04-06	2005-12-27	Perricone Nicholas V	Treatment of skin damage using polyenylphosphatidycholine
US6932963B2 (en)	2000-06-23	2005-08-23	Nicholas V. Perricone	Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
EP1417211B1 (fr)	2001-07-27	2007-05-30	Neptune Technologies & Bioressources Inc.	Phospholipides naturels d'origine marine contenant des flavonoides et des acides gras polyinsatures, et leurs applications
ATE350047T1 (de) *	2001-10-25	2007-01-15	Vladimir Leko	Zusammensetzung zum schutz und zur regeneration von leberstruktur und -funktion
US8052992B2 (en)	2003-10-22	2011-11-08	Enzymotec Ltd.	Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US7935365B2 (en)	2003-10-22	2011-05-03	Enzymotec, Ltd.	Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en)	2003-10-22	2005-06-16	Enzymotec Ltd.	Lipids containing omega-3 and omega-6 fatty acids
RU2283114C1 (ru) *	2005-06-07	2006-09-10	Открытое акционерное общество "Нижегородский химико-фармацевтический завод"	Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы
ES2657686T3 (es) *	2009-06-24	2018-03-06	Lipoid Gmbh	Composición para aplicaciones cosméticas, farmacéuticas o dietéticas
NO2493478T3 (fr)	2009-10-29	2018-07-21
CN105816422B (zh)	2015-01-05	2020-08-14	天士力医药集团股份有限公司	一种水飞蓟宾注射剂及其制备方法
CN105983015B (zh)	2015-03-23	2022-01-25	天士力医药集团股份有限公司	一种含有水飞蓟宾、ve的药物组合物
CN105983016B (zh)	2015-03-23	2023-08-11	天士力医药集团股份有限公司	一种含有水飞蓟宾的药物组合
ITUB20155532A1 (it) *	2015-11-12	2017-05-12	St Biochimico Italiano Giovanni Lorenzini Spa	Formulazione farmaceutica orale comprendente silibina
WO2019087084A1 (fr)	2017-11-02	2019-05-09	Eman Biodiscoveries Sd. Bhd.	Extrait d'orthosiphon stamineus, formulations et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR5060M (fr) *	1965-12-22	1967-05-08
FR2343481A1 (fr) *	1976-03-11	1977-10-07	Gerlich Norbert	Composition destinee a empecher les lesions des membranes biologiques et a regenerer ces membranes une fois qu'elles ont ete endommagees

1985
- 1985-07-17 IT IT21603/85A patent/IT1187687B/it active
1986
- 1986-07-07 DE DE8686109256T patent/DE3669106D1/de not_active Expired - Lifetime
- 1986-07-07 EP EP86109256A patent/EP0209037B1/fr not_active Expired - Lifetime
- 1986-07-07 AT AT86109256T patent/ATE50499T1/de not_active IP Right Cessation
- 1986-07-16 JP JP61167749A patent/JPS6222719A/ja active Pending
- 1986-07-17 CS CS865456A patent/CS261637B1/cs unknown

Also Published As

Publication number	Publication date
JPS6222719A (ja)	1987-01-30
EP0209037B1 (fr)	1990-02-28
DE3669106D1 (de)	1990-04-05
IT8521603A0 (it)	1985-07-17
EP0209037A1 (fr)	1987-01-21
IT1187687B (it)	1987-12-23
ATE50499T1 (de)	1990-03-15
CS545686A1 (en)	1988-07-15

Publication	Publication Date	Title
EP0209037B1 (fr)	1990-02-28	Compositions pharmaceutiques contenant des flavanolignanes et des phospholipides comme principes actifs
ES2704439T3 (es)	2019-03-18	Composiciones que comprenden monoglicéridos de ácidos grasos poliinsaturados o derivados de los mismos y usos de los mismos
ATE522211T1 (de)	2011-09-15	Stabilisierte fibrat-mikropartikel
HK1044720B (zh)	2006-08-18	必需脂肪酸在预防心血管疾病中的应用
BRPI0808945A2 (pt)	2014-08-26	Composição
CN1092973C (zh)	2002-10-23	乳香或乳香亲脂性提取物在制备用于治疗阿尔茨海默症的药物中的用途
EP0786993B1 (fr)	2002-06-05	Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et leur utilisation dans le traitement de troubles metaboliques et cardiovasculaires
CN100413492C (zh)	2008-08-27	口服给药治疗利什曼病的含有米替福星的固体药物组合物
KR100694907B1 (ko)	2007-03-14	아테롬성동맥경화 치료제로서의 프로안토시아니딘 ａ2의인지질 착체
OA12862A (en)	2006-09-15	Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone.
US6552070B2 (en)	2003-04-22	Health food useful for preventing liver and biliary dysfunctions containing an alkanoyl L-carnitine and Silybum marianum extract
WO2016065442A1 (fr)	2016-05-06	Compositions pharmaceutiques anti-inflammatoires, prolifératives, protectrices et mucoadhésives, solubles et stables, leur utilisation dans le traitement des tableaux de mucosite et leur procédé d'obtention, composition pharmaceutique de base pour la préparation de ces compositions pharmaceutiques et leur procédé d'obtention
KR101165934B1 (ko)	2012-07-19	혈관보호제들의 합제와 그들을 함유한 제제
US6001828A (en)	1999-12-14	Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection
CN100446763C (zh)	2008-12-31	含有联苯双酯和水飞蓟素的口服微乳剂组合物
NL8105635A (nl)	1983-07-01	Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
US20040006048A1 (en)	2004-01-08	Combination of lecithin with ascorbic acid
ITMI961010A1 (it)	1997-11-20	Composizioni farmaceutiche ciclosporina ed un veicolante compren- dente almeno un estere dell'acido a-glicerofosforico con colina
EP0087863A2 (fr)	1983-09-07	Composition pharmaceutique et diététique
CA2251656A1 (fr)	1997-10-30	Compositions pharmaceutiques contenant du tyloxapol pour administration par les voies respiratoires
ES2943388T3 (es)	2023-06-12	Composiciones sólidas en polvo que comprenden flavonoides, procedimiento para su preparación, formulaciones y uso de las mismas
GB2355930A (en)	2001-05-09	Injection of pantothenic acid for relief of pain in joints
KR20000012259A (ko)	2000-03-06	간질환 치료 및 예방용 의약 조성물
RU2002126216A (ru)	2004-03-20	Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени
KR102743328B1 (ko)	2024-12-16	염증 및 통증의 예방 및/또는 치료에 유용한 조성물.